OptimizeRx
OPRX
129 hedge funds and large institutions have $164M invested in OptimizeRx in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 22 closing their positions.
13,245% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $11K
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
3% more funds holding
Funds holding: 125 → 129 (+4)
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
0.33% less ownership
Funds ownership: 71.91% → 71.59% (-0.33%)
40% less capital invested
Capital invested by funds: $274M → $164M (-$110M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$4.82M |
| 2 |
GIPM
G2 Investment Partners Management
New York
|
+$2.13M |
| 3 |
II
Inspire Investing
Meridian,
Idaho
|
+$1.57M |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
+$1.46M |
| 5 |
Jane Street
New York
|
+$1.43M |
Top Sellers
| 1 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$4.63M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.08M |
| 3 |
HIS
Harvest Investment Services
Oakbrook Terrace,
Illinois
|
-$3.44M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.4M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.05M |
OPRX Hedge Fund Activity: Q4 2025 in Review
129 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q4 2025, worth a combined $164M — down 40% from $274M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new OPRX positions and 22 closed out — a net gain of 4 holders — while 39 added to existing stakes and 39 trimmed.
The largest buyer was Next Century Growth Investors, adding an estimated $4.82M. The largest seller was CenterBook Partners, cutting an estimated $4.63M.
- 129 institutional investors held OptimizeRx (OPRX) as of Q4 2025, up from 125 in Q3 2025.
- Funds reported $164M of OptimizeRx stock for Q4 2025, down 40% quarter-over-quarter.
- 26 funds opened new OptimizeRx positions in Q4 2025 and 22 closed out, a net change of +4 holders.
- The largest OptimizeRx buyer in Q4 2025 was Next Century Growth Investors, an estimated $4.82M added.
- The largest OptimizeRx seller in Q4 2025 was CenterBook Partners, an estimated $4.63M sold.
Based on aggregated 13F filings for Q4 2025.